Peer-reviewed veterinary case report
Kidney disease dogs on enalapril or telmisartan and SDMA levels
By Nasr, Amirah et al.·Published in Frontiers in veterinary science·2024·Department of Small Animal Medicine and Surgery, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Serum symmetric dimethylarginine concentrations in enalapril- or telmisartan-treated dogs with proteinuric chronic kidney disease.
- Species:
- dog
Plain-English summary
A group of dogs with chronic kidney disease (CKD) were treated with either enalapril or telmisartan, medications that help reduce kidney pressure and protein loss. The study looked at how these treatments affected a specific kidney function marker called serum symmetric dimethylarginine (SDMA). After 30 days, dogs treated with both medications showed a slight decrease in SDMA levels, while those on enalapril alone had no significant change. Overall, the treatments helped manage kidney function without causing major fluctuations in SDMA levels, indicating they were effective for these dogs.
People also search for: dog chronic kidney disease treatment · enalapril for dogs kidney disease · telmisartan for dogs with proteinuria
Abstract
INTRODUCTION: Renin-angiotensin-aldosterone system inhibition (RAASi) reduces intraglomerular pressure and is a standard therapy for dogs with proteinuric chronic kidney disease (CKD). RAASi can acutely decrease glomerular filtration rate (GFR); however, its effects on the marker of GFR serum symmetric dimethylarginine (SDMA) concentration in dogs have not been specifically evaluated. The objective of this study was to evaluate changes, relative to pretreatment values, in serum SDMA concentrations in dogs with proteinuric CKD receiving RAASi therapy. METHODS: This retrospective study used banked samples from 29 dogs with proteinuric CKD treated with enalapril (0.5 mg/kg PO q12h; = 16) or telmisartan (1 mg/kg PO q24h; = 13) alone ( = 22) or in combination with amlodipine if severely hypertensive ( = 7). Serum SDMA, creatinine, and urea nitrogen (SUN) concentrations were measured before and 7 and 30 days after starting RAASi. Percentage and absolute changes in these biomarkers were calculated for each dog and time point. A linear mixed model was used to test whether changes significantly differed from zero ( < 0.05). RESULTS: Overall, mean ± SEM Day 7 and 30 percentage change in SDMA were  - 4.8 ± 3.6% and  - 3.2 ± 3.4%, respectively; in creatinine were 7.4 ± 3.3% and 3.0 ± 3.1%, respectively; and in SUN were 22.1 ± 6.8% and 16.7 ± 6.2%, respectively. Mean changes varied according to whether all dogs, those on RAASi alone, or those co-treated with amlodipine were evaluated. In dogs receiving RAASi alone, at day 7, there were significant mean percentual increases in creatinine (9%; = 0.023) and SUN (23%; = 0.005), but SDMA was unchanged. In dogs co-treated with amlodipine, a significant absolute decrease in mean SDMA (-2.29 μg/dL; = 0.026) occurred at days 7 and 30, while mean creatinine was unchanged and mean SUN increased. DISCUSSION: Proteinuric dogs receiving RAASi had low-magnitude changes in serum SDMA and creatinine, and moderate-magnitude changes in SUN concentrations. The direction of change in SDMA did not consistently match that of creatinine and SUN.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/39711803/